Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry

By sjmartinez • October 19, 2024

Amubieya O, Todd JL, Neely ML, Kaner RJ, Lasky JA, Namen A, Hesslinger C, Palmer SM, Weigt SS, Belperio JA. Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry. PLoS One. 2024 Oct 17;19(10):e0312044. doi: 10.1371/journal.pone.0312044. PMID: 39418259; PMCID: PMC11486396.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV

Zanni MV, Umbleja T, Fichtenbaum CJ, Fitch KV, McCallum S, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Schnittman SR, Erlandson KM, Diggs[...]

Social genomics, cognition, and well-being during the COVID-19 pandemic

Bateman JR, Krishnamurthy S, Quillen EE, Waugh CE, Kershaw KN, Lockhart SN, Hughes TM, Seeman TE, Cole SW, Craft S. Social genomics, cognition, and well-being[...]

Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT

Finn RS, Qin S, Piscaglia F, Evans TRJ, Knox JJ, López López C, Ramji Z, Ren M, Mody K, Vogel A, Kudo M. Characterization of[...]